바로가기메뉴

본문 바로가기 주메뉴 바로가기

Dexamethasone and COVID-19 in a Developing Country: Appropriate Use?

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2021, v.84 no.3, pp.248-249
https://doi.org/10.4046/trd.2021.0081
Diego Martin Moreno Marreros (Division of Internal Medicine, Hospital II Chocope-EsSalud, Ascope)
Maycol Leonardo Aburto Moreno (Division of Internal Medicine, Hospital de Alta Complejidad Virgen de la Puerta, Trujillo, Peru)
Kattia Gassely Torres Gil (Division of Internal Medicine, Hospital II Chocope-EsSalud, Ascope)
Carlos Morera Guzman (Division of Internal Medicine, Hospital II Chocope-EsSalud, Ascope)
  • Downloaded
  • Viewed

Abstract

keywords

Reference

1.

1. Lee HW, Park J, Lee JK, Park TY, Heo EY. The effect of the timing of dexamethasone administration in patients with COVID-19 pneumonia. Tuberc Respir Dis 2021 Mar 29 [Epub]. https://doi.org/10.4046/trd.2021.0309.

2.

2. RECOVERY Collaborative Group; Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021;384:693-704.

3.

3. Bahl A, Johnson S, Chen NW. Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients. Int Emerg Med 2021 Feb 5 [Epub]. https://doi.org/10.1007/s11739-021-02655-6.

4.

4. Medina ML, Dominguez KC. Self-medication in adults attending the drugstores of the Jesús Nazareno District, Ayacucho 2015. An Fac Med 2016;77:387-92.

5.

5. Hermoza-Moquillaza R, Loza-Munarriz C, Rodríguez-Hurtada D, Arellano-Sacramento C, Hermoza-Moquillaza V. Selfmedication in district of Lima Metropolitan, Peru. Rev Med Hered 2016;27:15-21.

Tuberculosis & Respiratory Diseases